home subscribe search archive forthcoming

Editor-in-Chief

Janice M. Reichert, Ph.D.
Senior Research Fellow
Tufts Center for the Study of Drug Development
Boston, Massachusetts USA

Dr. Reichert has studied innovation in the pharmaceutical and biotechnology industries at the Tufts Center for the Study of Drug Development since 1999. Her work includes strategic analyses of candidate and approved products, including clinical development and approval times, phase transition probabilities, and approval success rates for new therapeutics and vaccines. These analyses have been featured in over 25 publications by Dr. Reichert. Her recent work includes studies of monoclonal antibodies as cancer therapeutics and as antiviral drugs.

Dr. Reichert has presented her research results as an invited speaker at conferences in the United States, Canada, Europe and China. She was co-chair of the Massachusetts Biotechnology Council's Clinical Trials Committee for five years and has served on the editorial boards of three journals. In addition, Dr. Reichert regularly provides input to various government, non-profit, and industry organizations such as the National Institutes of Health, the Organization for Economic Cooperation and Development, the International AIDS Vaccine Initiative, and the Biotechnology Industry Organization.

Dr. Reichert received her Ph.D. in organic chemistry from the University of Pennsylvania and her postdoctoral training as a National Institutes of Health Research Fellow at Harvard Medical School. Before joining the Tufts Center for the Study of Drug Development, Dr. Reichert performed drug discovery research and preclinical development at several companies in the Boston area.

Editorial Board

Gregory P. Adams, Ph.D.
Fox Chase Cancer Center, Philadelphia, PA USA
Joseph P. Balthasar, Ph.D.
State University of New York at Buffalo, Buffalo, NY USA
Alain Beck, Ph.D.
Centre d'Immunologie Pierre Fabre, St. Julien-en-Genevois, France
Sally Bolmer, Ph.D., RAC
Human Genome Sciences, Inc, Rockville, MD USA
Pavel V. Bondarenko, Ph.D.
Amgen, Thousand Oaks, CA USA
Andrew Bradbury, M.B., Ph.D.
Los Alamos National Laboratory, Los Alamos, NM, USA
John C. Byrd, M.D.
The Ohio State University, Columbus, OH USA
Paul J. Carter, Ph.D.
Seattle Genetics, Inc., Bothell, WA USA
Michel Chartrain, Ph.D.
Merck & Co., Inc., Rahway, NJ USA
Vijay. K. Chaudhary, M.Sc., Ph.D.
University of Delhi South Campus, New Delhi, India
Raphael Clynes, M.D., Ph.D.
Columbia University, New York, NY USA
Nathalie Corvaia, Ph.D.
Centre d'Immunologie Pierre Fabre, St Julien-en-Genevois, France
Graeme Currie, Ph.D.
PDL Biopharma, Redwood City, CA USA
John R. Desjarlais, Ph.D.
Xencor, Inc., Monrovia, CA USA
Dimiter S. Dimitrov, Ph.D.
NCI, NIH, Frederick, MD USA
Stefan Dübel, Ph.D.
Technical University of Braunschweig, Braunschweig, Germany
Martin Glennie, Ph.D.
University of Southampton, Southampton, UK
David Glover, M.A., M.B.
MedCell Bioscience, Ltd., Fordham Nr Newmarket, UK
Yajun Guo, M.D., Ph.D.
Second Military Medical University, Shanghai, China
Raffit Hassan, M.D.
NCI, NIH, Bethesda, MD USA
P. Mark Hogarth, Ph.D.
Burnet Institute, Heidelberg, Victoria Australia
Hennie R. Hoogenboom, Ph.D.
Ablynx, Ghent, Belgium
James S. Huston, Ph.D.
EMD Serono - Lexigen Research Center, Billerica, MA USA
Roy Jefferis, Ph.D.
University of Birmingham, Birmingham, UK
Gaurav Laroia, Ph.D.
Merck & Co., Inc., Whitehouse Station, NJ USA
Marie-Paule Lefranc, Ph.D.
Universite Montpellier, Montpellier, France
Nils Lonberg, Ph.D.
Medarex, Milpitas, CA USA
Henry Lowman, Ph.D.
Genentech, South San Francisco, CA USA
James D. Marks, M.D., Ph.D.
University of California, San Francisco, San Francisco, CA USA
John L. Marquardt, Jr., J.D., M.B.A., Ph.D.
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, Washington D.C. USA
R.A. Mashelkar, Ph.D., F.R.S.
National Chemical Laboratory, Pune, India
John McCafferty, Ph.D.
University of Cambridge, Cambrige UK
Jan ter Meulen, M.D.
Merck Research Laboratories, West Point, PA USA
Sherie Morrison, Ph.D.
University of California, Los Angeles, Los Angeles, CA USA
Jan Mueller-Berghaus, M.D.
Paul-Ehrlich-Institute, Langen, Germany
Dario Neri, Ph.D.
Swiss Federal Institute of Technology, Zurich, Switzerland
Gilles Paintaud, Ph.D.
François Rabelais University and CNRS, Tours, France
Ira Pastan, M.D.
NCI, NIH, Bethesda, MD USA
Andre Pelegrin, Ph.D.
INSERM, Montpellier, France
Andreas Plückthun, Ph.D.
Universitaet Zurich, Zurich, Switzerland
Leonard Presta, Ph.D.
Schering-Plough Biopharma, Palo Alto, CA USA
Mitsuo Satoh
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan
Christian K. Schneider, M.D.
Paul-Ehrlich-Institut (PEI), Langen, Germany, European Medicines Agency (EMEA), London, UK
Jamie Kathleen Scott, M.D., Ph.D.
Simon Fraser University, Burnaby, BC Canada
Kiran Mazumdar Shaw
Biocon, Ltd., Bangalore, India
Sachdev Sidhu, Ph.D.
University of Toronto, Toronto, ON Canada
Arne Skerra, Ph.D.
Technische Universitaet Muenchen, Freising-Weihenstephan, Germany
Jean-Luc Teillaud, Dr.Sc.
Centre de Recherche des Cordeliers/INSERM, France
Pablo Umana, Ph.D.
Glycart Biotechnology AG (Roche Group), Zurich, Switzerland
E. Sally Ward, Ph.D.
University of Texas, Southwestern, Dallas, TX USA
Herve Watier, M.D., Ph.D.
Universite Framcpos-Rabelis de Tours and CNRS, Tours, France
Louis M. Weiner, M.D.
Georgetown University Medical Center, Washington D.C, USA
Jan van de Winkel, Ph.D.
Genmab, Utrecht, The Netherlands
Sir Gregory Winter, C.B.E, F.R.S.
MRC Laboratory of Molecular Biology, Cambridge, UK
K. Dane Wittrup, Ph.D.
Massachusetts Institute of Technology, Cambridge, MA USA
Jenny M. Woof, Ph.D.
University of Dundee Medical School, Dundee, UK
Herren Wu, Ph.D.
MedImmune, Inc., Gaithersburg, MD USA
Thierry Wurch, Ph.D.
Institut de Recherche Pierre Fabre, St. Julien-en-Genevois, France
Bodi Zhang, M.D.
Tufts University, Boston, MA USA